Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06276803 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The LINFU® U.S. Registry for the in the General Population Without Risk Factors

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 15, 2024 to Sep 15, 2024
    • Primary completion date: Apr 15, 2034 to Sep 15, 2034
    • Study completion date: Jun 15, 2034 to Dec 15, 2034
    v5
  2. Start date: Apr 15, 2024 to Jun 15, 2024v4
  3. Eligibility criteria expanded, about 20 wordsv3
  4. Study description expanded, about 16 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions.. In this study, LINFU® will be evaluated in the general population with no risk factors and who exhibit no signs or symptoms of disease, This study will help determine if LINFU® can be used to help identify early, asymptomatic pancreatic ductal adenocarcinoma (PDAC) or their precursor lesions (PanIn-2, PanIn-3).
Trial Details
NCT Number NCT06276803
Lead Sponsor Adenocyte, LLC
Conditions
(from sponsor)		 Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Dysplasia
Related terms Pancreatic Neoplasms
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov